Benefits of Pygeum

Evidence-Based Benefits

• BPH symptom relief — Wilt et al. (2002) Cochrane review of 18 RCTs involving 1,562 men concluded that pygeum extract provided moderate improvement in overall urological symptoms and flow measures, with men taking pygeum more than twice as likely to report symptom improvement
• Nocturia reduction — the Cochrane review found a 19% reduction in nighttime urination frequency, which is particularly meaningful for sleep quality in men with BPH
• Anti-inflammatory mechanism — pentacyclic triterpenes (ursolic acid, oleanolic acid) inhibit 5-lipoxygenase and cyclooxygenase in prostate tissue, reducing prostaglandin and leukotriene-driven inflammation
• Growth factor inhibition — pygeum extract inhibits fibroblast growth factors (FGF) and epidermal growth factor (EGF) in prostate tissue, which may slow prostatic hyperplasia progression
• Secretory function — ferulic acid esters (n-docosanol) in pygeum improve prostatic secretory function and may reduce the frequency and volume of prostatic fluid abnormalities associated with BPH

What the Research Says

Pygeum is a well-researched supplement for prostate health, particularly for managing symptoms of benign prostatic hyperplasia (BPH). A 2002 Cochrane review by Wilt et al. analyzed 18 randomized controlled trials involving 1,562 men with BPH and found that pygeum bark extract (typically 100mg daily standardized to Tadenan specifications) significantly improved overall urological symptoms in 65% of users compared to 30% for placebo. The extract also reduced nocturia by 19%, residual urine volume by 24%, and increased peak urine flow by 23%. These findings were corroborated by a systematic review and meta-analysis by Ishani et al. (2000), which included the same dataset.

Edgar et al. (2007) provided insights into pygeum's mechanisms of action, confirming its anti-inflammatory effects via 5-LOX inhibition and anti-proliferative effects through growth factor inhibition. Additionally, a study by Piquero-Casals et al. (2025) demonstrated that pygeum supplementation increased hair density in individuals with chronic telogen effluvium or androgenetic alopecia, suggesting broader applications beyond prostate health.

Pygeum is an approved pharmaceutical product in France, Germany, and Italy, covered by national health insurance. However, sustainability concerns exist as Prunus africana is listed under CITES Appendix II due to overharvesting, emphasizing the need for ethical sourcing.

Related Conditions